Is there any predictor for relapse after treatment withdrawal in autoimmune hepatitis patients in the real life?. (7th February 2022)

• Record Type: Journal Article
• Authors: Çavuş, Bilger; Akyuz, Filiz; İliaz, Raim; Atasoy, Alp; Akyuz, Umit; Demir, Kadir; Besisik, Fatih; Kaymakoglu, Sabahattin
• Is Part Of: International journal of immunopathology and pharmacology. Volume 36(2022)
• Publication Date: 2022-02-07
• Subjects: Autoimmune hepatitis -- treatment withdrawal -- cirrhosis; Immunopathology -- Periodicals; Pharmacology -- Periodicals; Inflammation -- Periodicals; 615.1
• DOI: 10.1177/03946320221077860
• Languages: English
• ISSNs: 0394-6320

Abstract

Backgrounds and Aims: In autoimmune hepatitis, there are uncertainties about whether to discontinue the treatment, when the treatment should be discontinued, and the risks of relapse in the cases where remission is achieved with immunosuppressive therapy. In this study, patients with AIH, whose immunosuppressive treatments were discontinued, were evaluated for the rates of remission and the risk of relapse. Materials and Methods: A total of 119 patients, who were diagnosed with AIH based on the AIHG scoring systems between 1990 and 2015, were evaluated. Patients were receiving standard azathioprine and steroid therapy. The treatment was discontinued in patients, who had been receiving treatment for at least 2 years, who had no clinical complaints, and whose aminotransferases were normal and when an increase occurred in AST values more than two times the normal after the treatment was interrupted, the case was considered as a relapse. Results: Among the patients, 83%( n = 99) were women. When the patients were diagnosed with AIH, their mean age was 36 ± 16(8–79) years; 70.6%( n = 84) were type 1, 3.4%( n = 4) type 2, and 26%( n = 31) were autoantibody-negative AIH. At the time of discontinuation, liver biopsy was performed in 8 of the patients and minimal-mild abnormalities were detected. Patients whose treatment was discontinued received treatment for an average of 101 ± 75(range: 24–280, median: 68.5) months; and, they were followed up for an average of 19 (1–110) months during the period without medication. Relapse occurred in 67%( n = 12) of the patients with drug withdrawal. Relapse occurred within the first 12 months in 67% of these patients ( n = 8) and developed with an acute hepatitis attack in 42%. None of the clinical, laboratory, and histological data were found to be effective on relapse. Conclusion: In patients with AIH, relapse occurs in two-thirds of patients within an average of 19 month after the discontinuation of the medication. Most relapses occur at the early period and they are accompanied by an acute hepatitis attack.